Results 171 to 180 of about 13,113,839 (405)

Accuracy of heart failure ascertainment using routinely collected healthcare data: a systematic review and meta-analysis

Systematic Reviews
Background Ascertainment of heart failure (HF) hospitalizations in cardiovascular trials is costly and complex, involving processes that could be streamlined by using routinely collected healthcare data (RCD).
Michelle. A. Goonasekera, Alison Offer, Waseem Karsan, Muram El-Nayir, Amy E. Mallorie, Sarah Parish, Richard J. Haynes, Marion M. Mafham   +7 more
doaj   +1 more source

CTP-LLM: Clinical Trial Phase Transition Prediction Using Large Language Models [PDF]

arXiv
New medical treatment development requires multiple phases of clinical trials. Despite the significant human and financial costs of bringing a drug to market, less than 20% of drugs in testing will make it from the first phase to final approval. Recent literature indicates that the design of the trial protocols significantly contributes to trial ...
arxiv  

Comparing Biomarkers as Trial Level General Surrogates [PDF]

arXiv, 2015
An intermediate response measure that accurately predicts efficacy in a new setting can reduce trial cost and time to product licensure. In this paper, we define a trial level general surrogate as a trial level intermediate response that accurately predicts trial level clinical responses.
arxiv  

Clinical Trial of Phenylindanedione as an Anticoagulant [PDF]

, 1953
M. Toohey
openalex   +1 more source

Robust acute myeloid leukemia engraftment in humanized scaffolds using injectable biomaterials and intravenous xenotransplantation

Molecular Oncology, EarlyView.
Patient‐derived xenografts (PDXs) can be improved by implantation of a humanized niche. We tested different biomaterials and approaches, and demonstrate that the combination of an injectable biomaterial for scaffold creation plus an intravenous route for acute myeloid leukemia (AML) xenotransplantation provide the most convenient and robust approach to
Daniel Busa, Zdenka Herudkova, Jan Hyl, Jakub Vlazny, Filip Sokol, Kvetoslava Matulova, Adam Folta, Jakub Hynst, Lucy Vojtova, Leos Kren, Martin Repko, Zdenek Racil, Jiri Mayer, Martin Culen   +13 more
wiley   +1 more source

The Planniing and Problems of Clinical Trials [PDF]

, 1965
R. W. P. McWhirter
openalex   +2 more sources

A novel photocleavable amino-modified graphene for covalent purification of N-glycans from hepatocellular carcinoma patients’ serum for potential biomarkers discovery

Cancer Nanotechnology
Glycosylation alterations have emerged as significant indicators in the landscape of cancer diagnosis, with aberrant N-glycans standing out as potential biomarkers.
Xuyuan Chao, Shengjie Yang, Baoying Zhang, Xin Zang, Jingyi Zhang, Xizi Liu, Lu Chen, Lu Qi, Xiaofeng Xue, Han Hu, Xinghe Wang   +10 more
doaj   +1 more source

Automatically Labeling Clinical Trial Outcomes: A Large-Scale Benchmark for Drug Development [PDF]

arXiv
Background The cost of drug discovery and development is substantial, with clinical trial outcomes playing a critical role in regulatory approval and patient care. However, access to large-scale, high-quality clinical trial outcome data remains limited, hindering advancements in predictive modeling and evidence-based decision-making.
arxiv  

Treatment Effect Quantification for Time-to-event Endpoints -- Estimands, Analysis Strategies, and beyond

, 2018
A draft addendum to ICH E9 has been released for public consultation in August 2017. The addendum focuses on two topics particularly relevant for randomized confirmatory clinical trials: estimands and sensitivity analyses.
Rufibach, Kaspar
core   +1 more source

Preliminary Clinical Trials with 9-Alpha-Fluoro Hydrocortisone Acetate in Rheumatoid Arthritis [PDF]

, 1954
Edward W. Boland, Nathan E. Headley
openalex   +1 more source